Innovations In Clinical Neuroscience

NOV-DEC 2017

A peer-reviewed, evidence-based journal for clinicians in the field of neuroscience

Issue link: https://innovationscns.epubxp.com/i/924986

Contents of this Issue

Navigation

Page 28 of 83

29 ICNS INNOVATIONS IN CLINICAL NEUROSCIENCE November-December 2017 • Volume 14 • Number 11–12 O R I G I N A L R E S E A R C H 11. Arango C, Amador X. Lessons learned about poor insight. Schizophr Bull. 2011;37:27–28. 12. Pijnenborg GHM, Donkersgoed RJM, David AS, Aleman A. Changes in insight during treatment for psychotic disorders: a meta-analysis. Schizophrenia Research. 2013;144: 109–117. 13. David AS. Insight and psychosis. Br J Psychiatr. 1990;156:798–808. 14. Parellada M, Boada L, Fraguas D, et al. Trait and state attributes of insight in first episodes of early-onset schizophrenia and other psychoses: a 2-year longitudinal study. Schizophr Bull. 2011;37:38–51. 15. Gould F, McGuire LS, Durand D, et al. Self- assessment in schizophrenia: accuracy of evaluation of cognition and everyday functioning. Neuropsychology. 2015;29:675–682. 16. Reddy LF, Horan WP, Barch DM, et al. Effort-based decision-making paradigms for clinical trials in schizophrenia: Part 1-psychomatric characteristics of 5 paradigms. Schizophr Bull. 2015;44:1045– 1054. 17. Sabbag S, Twamley EM, Vella L, et al. Assessing everyday functioning in schizophrenia: Not all informants seem equally informative. Schizophr Res. 2011; 131:250–255. 18. Kurtz MM, Tolman A. Neurocognition, insight into illness and subjective quality-of-life in schizophrenia, what is their relationship? Schizophr Res. 2011;127:157–162. 19. Tolman A, Kurtz MM. Neurocognitive predictors of objective and subjective quality of life in individuals with schizophrenia: a meta-analytic investigation. Schizophr Bull. 2012;38:304–315. 20. Sellwood W, Morrison AP, Beck R, et al. Subjective cognitive complaints in schizophrenia, relation to antipsychotic medication dose, actual cognitive performance, insight and symptoms. PLoS One. 2013;8: https://doi.org/10.1371/journal. pone.0083774. Accessed June 11, 2017. 21. Cuffel BJ, Alford J, Fischer EP, et al. Awareness of illness in schizophrenia and out-patient treatment compliance. J Nerv Ment Dis. 1996;184:653–659. 22. Loebel A, Cucchiaro J, Sarma K, et al. Efficacy and safety of lurasidone 80 mg/day and 160 mg/day in the treatment of schizophrenia: a randomized, double-blind, placebo- and active-controlled trial. Schizophr Res. 2013;145:101–109. 23. Loebel A, Cucchiaro J, Xu J, et al. Effectiveness of lurasidone vs quetiapine XR for relapse prevention in schizophrenia: a 12-month, double-blind, continuation study. Schizophr Res. 2013;147:95–102. 24. Lysaker P, Bell M. Insight and cognitive impairment in schizophrenia: performance on repeated administrations of the Wisconsin Card Sorting Test. J Nerv Ment Dis. 1994;182:656–660. 25. Sanz M, Constable G, Lopez-Ibor I, et al. A comparative study of insight scales and their relationship to psychopathological and clinical variables. Psychol Med. 1998;28:437–466. 26. Roseman AS, Kasckow J, Fellows I, et al. Insight, quality of life, and functional capacity in middle- aged and older adults with schizophrenia. Int J Geriatr Psychiatry. 2008;23:760–765. 27. Misiak B, Frydecka D, Beszłej JA, et al. Effects of antipsychotics on insight in schizophrenia: results from independent samples of first- episode and acutely relapsed patients. Int Clin Psychopharmacol. 2016;31:185–91. 28. Markova IS, Berrios GE. The assessment of insight in clinical psychiatry: a new scale. Acta Psychiatrica Scandinavica. 1992;86:159–164. 29. Pietrzak RH, Olver J, Norman T, et al. A comparison of the CogState schizophrenia battery and the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) battery in assessing cognitive impairment in chronic schizophrenia. J Clin Exp Neuropsychol. 2009;31:848–859. 30. Mausbach BT, Harvey PD, Goldman SR, et al. Development of a brief scale of everyday functioning in persons with serious mental illness. Schizophr Bull. 2007; 33:1364–1372. 31. Kaplan RM, Sieber WJ, Ganiats TG. The quality of well-being scale: comparison of the interviewer- administered version with a self-administered questionnaire. Psychol Health. 1997;12;783–791. 32. Seiber WJ, Groessl EJ, David KM, et al. Quality of Well Being Self-administered (QWB-SA) scale: user's manual https://hoapucsdedu/qwb-info/ QWB-Manual.pdf. 2008. Accessed June 11, 2017. 33. Fitzmaurice GM, Laird NM, Ware JH. Applied Longitudinal Analysis. New Jersey: John Wiley and Sons, Inc; 2004. 34. Harvey PD, Siu CO, Hsu J, et al. Effect of lurasidone on neurocognitive performance in patients with schizophrenia: a short-term placebo- and active- controlled study followed by a 6-month double- blind extension. Eur Neuropsychopharmacol. 2013;3:1373–1382. 35. Harvey PD, Siu CO, Ogasa M, Loebel A. Effect of lurasidone dose on cognition in patients with schizophrenia: post-hoc analysis of a long-term, double-blind continuation study. Schizophr Res. 2015;166:334–338. 36. Wilson WH, Ban TA, Guy W. Flexible system criteria in chronic schizophrenia. Compr Psychiatry J. 1986;27:259–265. 37. Amador XF, Strauss DH. Poor insight in schizophrenia. Psychiatr. 1993;Q64:305–318. 38. Lysaker PH, Buck KD, Salvatore G, et al. Lack of awareness of illness in schizophrenia, conceptualizations, correlates and treatment approaches. Expert Rev Neurother. 2009; 9:1035–1043. 39. Durand D, Strassnig M, Sabbag S, et al. Factors influencing self-assessment of cognition and functioning in schizophrenia, implications for treatment studies. Eur Neuropsychopharmacol. 2015;25:185–191. 40. Lincoln TM, Lullmann E, Rief W. Correlates and long-term consequences of poor insight in patients with schizophrenia: a systematic review. Schizophr Bull. 2007;33: 1324–1342. 41. Xavier RM, Pan W, Dungan JR, et al. Unraveling interrelationships among psychopathology symptoms cognitive domains and insight dimensions in chronic schizophrenia. Schizophr Res. 2017; in press. 42. Hopkins SC, Ogirala A, Loebel A, Koblan KS. Transformed PANSS factors intended to reduce pseudospecificity among symptom domains and enhance understanding of symptom change in antipsychotic-treated patients with schizophrenia. Schizophr Bull. 2017; in press. 43. McEvoy JP, Johnson J, Perkins D, et al. Insight in first-episode psychosis. Psychol Med. 2006;36: 1385–1393. ICNS

Articles in this issue

Links on this page

Archives of this issue

view archives of Innovations In Clinical Neuroscience - NOV-DEC 2017